Overview

A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis

Status:
Completed

Trial end date:
2019-01-25

Target enrollment:

Participant gender:

Summary

This first in human study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-06826647 in healthy subjects and subjects with plaque psoriasis.

Phase:

Phase 1

Details

Lead Sponsor:

Pfizer

Treatments:

Pharmaceutical Solutions